Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus REGROTON.
DEMI-REGROTON vs REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination